Carlsbad – September 08, 2026 -- Tyra Biosciences, Inc. (Nasdaq: TYRA) will disclose initial clinical results from its SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC) during a conference call scheduled for September 9, 2026, at 8:00 am ET.
Tyra sets September 9 call to unveil first SURF302 data
The clinical-stage biotech confirmed the call and webcast will present initial efficacy and safety data from the ongoing SURF302 trial, marking the first public disclosure of results for dabogratinib in this bladder cancer indication.
Dabogratinib targets FGFR3-driven tumors as lead pipeline asset
Dabogratinib is Tyra's lead precision medicine candidate, developed as a potential first-in-class selective FGFR3 inhibitor. Beyond IR NMIBC, the company is advancing the drug for low-grade upper tract urothelial cancer (LG-UTUC) and achondroplasia (ACH).
Access details published for investors and analysts
Participants can view the live webcast and slide presentation via the "For Investors" section of Tyra's website, with telephone access requiring advance registration for a dial-in number, passcode and registrant ID. The company will archive a replay on its site for at least 90 days following the event.
Pipeline extends beyond dabogratinib into liver and bile duct cancers
Tyra's broader FGFR-focused pipeline includes TYRA-430, an FGFR4/3-biased inhibitor in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an FGFR1/2/3 inhibitor being tested in the SURF201 study for metastatic intrahepatic cholangiocarcinoma.